Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1991006310) LIPOSOMAL COMPOSITIONS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/006310 International Application No.: PCT/US1990/006291
Publication Date: 16.05.1991 International Filing Date: 30.10.1990
Chapter 2 Demand Filed: 23.05.1991
IPC:
A61K 9/127 (2006.01) ,A61K 31/35 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
127
Liposomes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
Applicants:
THE LIPOSOME COMPANY, INC. [US/US]; One Research Way Princeton Forrestal Center Princeton, NJ 08540, US
Inventors:
BOLCSAK, Lois, E.; US
Agent:
BLOOM, Allen; The Liposome Company, Inc. One Research Way Princeton Forrestal Center Princeton, NJ 08540, US
Priority Data:
429,27830.10.1989US
Title (EN) LIPOSOMAL COMPOSITIONS
(FR) COMPOSITIONS LIPOSOMIQUES
Abstract:
(EN) Liposomal Cromolyn formulations comprising sodium cromoglycate and a lipid or lipid mixture are disclosed. The lipids employed in the cromolyn liposomal formulations of this invention include cholesterol neutralized cholesterol hydrogen succinate (cholesterol hemisuccinate or ''CHS''); saturated phospholipids such as dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), hydrogenated soy phosphatidylcholine (HSPC); and cholesterol (Chol), or mixtures of same.
(FR) Formulations liposomiques de cromoglycate comprenant du cromoglycate disodique ainsi qu'un lipide ou un mélange lipidique. Les lipides employés dans les formulations liposomiques de cromoglycate de l'invention, comprennent du succinate d'hydrogène de cholestérol neutralisé en cholestérol (hémisuccinate de cholestérol ou ''CHS''); des phospholipides saturés tels que dimiristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), phosphatidylcholine de soja hydrogénée (PCSH); du cholestérol (Chol), ou leurs mélanges.
Designated States: CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0500802JPH05501714CA2066698